

4<sup>th</sup> July, 2022

To, BSE Limited Corporate Relation Department PhirozeJeejeeboi Towers, Dalal Street, Mumbai - 400001. Scrip Code: 524404

National Stock Exchange of India Limited Listing Department Exchange Plaza, C-1, Block-G, Bandra-Kurla Complex, Bandra (East), Mumbai -400051. Symbol: MARKSANS

Sub.: Board of Directors of Marksans Pharma Limited ('the Company') to consider the Buyback of Equity Shares

Reg.: Intimation under regulation 29(1)(b) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015

Dear Sir/Madam,

In terms of Regulation 29(1)(b) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform you that a meeting of the Board of Directors of the Company is scheduled to be held on Friday, 8<sup>th</sup> July, 2022 to consider the proposal for buyback of fully paid up equity shares of the Company upto such amount of the aggregate of Company's paid up equity share capital and free reserves as the Board may decide in accordance with the provisions of Section 68, 69 and 70 of the Companies Act, 2013 and the SEBI (Buyback of Securities) Regulations, 2018.

It is further submitted that in terms of the Company's Code of Conduct to Regulate, Monitor and Report Trading by designated persons framed pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015, as amended, the trading window for dealing in the shares of the Company for the designated person(s) is already closed w.e.f. July 01, 2022 and will remain closed till 48 hours after the declaration of unaudited financial results for the quarter ended June 30, 2022.

Kindly take the above on record.

Thanking you,

Yours Sincerely, For Marksans Pharma Limited

TWish

Harshavardhan Panigrahi Company Secretary

## Marksans Pharma Ltd

11th, Floor, "GRANDEUR", Opp. Gundecha Symphony, Veera Desai Extension Road, Oshiwara, Andheri (W), Mumbai - 400 053 • Tel. : +91 22 4001 2000 • Email : info@marksanspharma.com www.marksanspharma.com